All news from Anaesthesiology

Jury 'Still Out' on Adjuvant Therapy in Kidney Cancer

In an editorial published online September 1 in the Annals of Oncology, Giuseppe Procopio, MD, Department of Medical Oncology, Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy, and colleagues point out that in the pivotal trial of the adjuvant use of sunitinib (Sutent, Pfizer Inc), the drug did not improve overall survival, although there was an increase in disease-free survival